Abstract

PurposeTo determine serum 25(OH)D and 1,25(OH)2D relationship with hepatitis B vaccination (study 1). Then, to investigate the effects on hepatitis B vaccination of achieving vitamin D sufficiency (serum 25(OH)D ≥ 50 nmol/L) by a unique comparison of simulated sunlight and oral vitamin D3 supplementation in wintertime (study 2).MethodsStudy 1 involved 447 adults. In study 2, 3 days after the initial hepatitis B vaccination, 119 men received either placebo, simulated sunlight (1.3 × standard-erythema dose, 3 × /week for 4 weeks and then 1 × /week for 8 weeks) or oral vitamin D3 (1000 IU/day for 4 weeks and 400 IU/day for 8 weeks). We measured hepatitis B vaccination efficacy as percentage of responders with anti-hepatitis B surface antigen immunoglobulin G ≥ 10 mIU/mL.ResultsIn study 1, vaccine response was poorer in persons with low vitamin D status (25(OH)D ≤ 40 vs 41–71 nmol/L mean difference [95% confidence interval] − 15% [− 26, − 3%]; 1,25(OH)2D ≤ 120 vs ≥ 157 pmol/L − 12% [− 24%, − 1%]). Vaccine response was also poorer in winter than summer (− 18% [− 31%, − 3%]), when serum 25(OH)D and 1,25(OH)2D were at seasonal nadirs, and 81% of persons had serum 25(OH)D < 50 nmol/L. In study 2, vitamin D supplementation strategies were similarly effective in achieving vitamin D sufficiency from the winter vitamin D nadir in almost all (~ 95%); however, the supplementation beginning 3 days after the initial vaccination did not effect the vaccine response (vitamin D vs placebo 4% [− 21%, 14%]).ConclusionLow vitamin D status at initial vaccination was associated with poorer hepatitis B vaccine response (study 1); however, vitamin D supplementation commencing 3 days after vaccination (study 2) did not influence the vaccination response.Clinical trial registry numberStudy 1 NCT02416895; https://clinicaltrials.gov/ct2/show/study/NCT02416895; Study 2 NCT03132103; https://clinicaltrials.gov/ct2/show/NCT03132103.

Highlights

  • Discovery of the vitamin D receptor in almost all immune cells, and the many roles vitamin D has in innate and adaptive arms of immunity [1,2,3], highlight the importance of vitamin D in the regulation of immune responses [4]

  • Fewer participants tended to respond to the hepatitis B vaccination who had 25(OH) D < 50 nmol/L than those who were vitamin D sufficient at the time of initial vaccination (50% vs 58%, mean difference [95% confidence interval], − 8% [− 17%, 1%], P = 0.09, h = 0.16, Fig. 3a)

  • Fewer participants were hepatitis B vaccine responders when they presented with low serum 1,25(OH)2D compared to participants who presented with high serum 1,25(OH)2D at the time of initial vaccination

Read more

Summary

Introduction

Discovery of the vitamin D receptor in almost all immune cells, and the many roles vitamin D has in innate and adaptive arms of immunity [1,2,3], highlight the importance of vitamin D in the regulation of immune responses [4]. Hepatitis B vaccination has previously been shown to be influenced by genetics and lifestyle factors [13,14,15] with 10–15% of adults responding inadequately by producing too few antibodies, as dictated by an anti-hepatitis B surface antigen immunoglobulin G (IgG) concentration of less than 10 mIU/mL [16]. Those responding to the vaccination with IgG concentration of 10 mIU/ mL or more are generally accepted to be protected against infection clinically [16, 17]. The hepatitis B vaccination course presents a suitable model to study the influence of vitamin D on the secondary immune response because there is widespread inter-individual variability in the magnitude of the antibody response after the second vaccination, and it is more possible to control prior exposure than with other commonly experienced vaccines (e.g., influenza) [24]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call